Global Intracranial Aneurysm Market by Type (Surgical Clipping, Endovascular Coiling, and Other Types), By End User (Hospitals, Clinics, and Other End-Users), By Region and Companies -Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

In 2022, the global Intracranial Aneurysm market was valued at USD 1.2 Billion and is expected to reach USD 2.7 billion in 2032. This market is estimated to register a CAGR of 8.8 % between 2023 and 2032. In the upcoming years, market development is anticipated to be driven by the prevalence of brain aneurysms rising, and minimally invasive intracranial aneurysm treatments are being used more frequently.

A cerebral artery’s wall bulges due to an intracranial aneurysm. An abnormal ballooning, bleb, or widening is the outcome. Blood artery damage or trauma, hypertension, smoking, and hereditary predisposition are all risk factors for the development of a brain aneurysm. Treatment choices for cerebral aneurysms include medical therapy, surgical clipping, endovascular therapy, and coiling without or with adjunctive devices.

By Type Analysis

The Endovascular coiling segment dominated the market for intracranial aneurysms and accounted for the highest revenue share. The brain aneurysm is located using a catheter in this slightest intrusive procedure. The groin region is used to insert the catheter into the artery that has an aneurysm. To stop blood flow into the aneurysm, coils or liquids that cause embolization are inserted. In comparison to surgical clipping procedures, endovascular coiling has benefits like easier access to the vertebrobasilar system, multiple aneurysms in the distant region, and a quicker recovery time. As a result, the advantages provided by the endovascular coiling method are fueling the segment’s development.

However, the market for flow diverters is anticipated to have the greatest CAGR. The growth of the sector is being driven by a rise in product approvals as well as an increase in demand for minimum-invasive procedures. In the upcoming years, it is predicted that an increase in product approvals and a rise in demand for minimally invasive procedures will further the segment’s expansion.

By End-User Analysis

The intracranial aneurysm market was dominated by the hospital sector, which contributed to revenue. The expansion of hospitals worldwide, the use of cutting-edge medical technology in operating rooms and critical care units, and increased government funding for hospitals are all credited with this. To provide top-notch treatment, hospitals frequently use cutting-edge technology. These tools help produce better, quicker, and more accurate results in addition to simplifying treatment processes.

Hospitals have post-operative physical therapy equipment, making them better suited to manage any post-operative complications. Among the most difficult and important surgeries, intracranial aneurysm procedures rely on the reliable, high-quality supplies available in hospitals. Additionally, Patients frequently prefer hospitals to urgent care centers because they provide superior medical care and have access to cutting-edge technology. Therefore, the market growth is being considerably increased by these factors.

Key Market Segments:

Based on Type

• Surgical Clipping
• Endovascular Coiling
• Flow Diverters
• Other Types

Based on End-User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Other End-Users

Driving Factors

One major driver of the intracranial aneurysm market’s revenue growth is an increasing incidence of these lesions due to unhealthy behaviors like excessive smoking, alcohol consumption, and drug abuse. The market for intracranial aneurysms is experiencing revenue growth due to an aging population with a higher risk of developing one, as well as rising trauma incidences and blood pressure-related disorders. The intracranial aneurysm market is experiencing revenue growth due to increased disease and treatment awareness. Furthermore, this growth is being supported by an increase in clinical trials for drugs to treat them.

Restraining Factors

Patients without insurance or limited access to healthcare may face high costs for treating Intracranial Aneurysms. Patients may struggle to access treatment options and lack financial resources to cover necessary medical care. The general public often is unaware of the symptoms and dangers of Intracranial Aneurysms,  delayed diagnosis and treatment, and patient suffering.

There are alternative treatments for Intracranial aneurysms, such as endovascular coiling and flow diversion, which can be less invasive than surgery. patients may prefer less invasive options rather than surgery, these alternatives could limit access to surgical solutions.

Growing Opportunities

Due to an aging population and factors like smoking and hypertension, the prevalence of intracranial aneurysms rising. Companies have a unique opportunity to create new devices and treatments to address this market need. Due to advances in medical technology, the treatment and diagnosis of intracranial aneurysms have become more accurate and precise. Companies now have the opportunity to develop treatments using these advances. Research and development of new treatments have seen an increase in investment. Companies now have the chance to develop devices and treatments that enhance patient outcomes while reducing the potential for complications.

Latest Trends

Endovascular coiling is anticipated to continue developing steadily in the future. A catheter is used in a minimally invasive way to treat a brain aneurysm by stopping blood from entering arteries. The benefits of this technique, such as easy access to the vertebrobasilar system, the ability to treat several aneurysms in difficult-to-reach places, and its quicker recovery time than other procedures, are what is causing the segment to grow. Also, there is a good chance that the increasing number of strokes that take place worldwide will rupture blood vessels and result in cerebral aneurysms, which will promote market revenue growth.

COVID-19 Impact Analysis

The impact of COVID-19 on the market for intracranial aneurysms is unfavorable. The COVID-19 pandemic’s effects do not exclude the neurosurgery field. Demand and production were immediately impacted by the COVID-19 pandemic, disrupting the supply chain and increasing costs for businesses. Brain surgeries have frequently been delayed or even canceled during this period in order to stop the coronavirus from spreading.

Regional Analysis

North America dominated the market for intracranial aneurysms and accounted for a revenue share. due to the presence of well-established healthcare facilities, a growingly older population, and a high prevalence of hypertension and stroke. The need for less invasive procedures and rising in the prevalence of cerebral aneurysms are also driving market development in the region. The industry is also expected to grow as a result of an increasing number of initiatives being introduced by various organizations.

The Bee Foundation (TBF), an organization dedicated to raising awareness and prevention of brain aneurysms through innovative research is dedicated to rising awareness and lowering the number of fatalities reasons by brain aneurysms. For instance, The Bee Foundation (TBF) is dedicated to increasing awareness and decreasing the incidence of brain aneurysm-related mortality through cutting-edge research. Applications are being accepted by the TBF for a brain aneurysm.

The market for intracranial aneurysms is Predicted to grow at the highest CAGR in the Asia Pacific region. This is due to many factors, including an aging population, various lifestyle stressors, an increase in the frequency of hypertension, a large population, better diagnosis quality, and rising patient affordability. The Asia Pacific region has seen a substantial increase in intracranial aneurysm surgeries as a result of all the aforementioned causes.

Key Regions and Countries:

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Market Share & Key Players Analysis:

Manufacturers in the intracranial aneurysms market are concentrating on the introduction of cutting-edge medical devices, business plans, and technical developments. Market participators are concentrating on applying tactics like marketing and promotions, broadening product portfolios, and rising the availability and reach of their product offerings to raise consumer knowledge of the benefit of intracranial aneurysms.

Market Key Players:

Listed below are some of the most prominent Intracranial Aneurysm Market players.

• Braun
• Delta Surgical
• Evonos Gmbh & Co. KG
• Integra Life-Science Holding Corporation
• Medtronic PLC
• Microport Scientific Corporation
• Mizuho Medical Incorporation
• Spiegelberg
• Stryker Corporation
• Terumo Global
• Johnson and Johnson Services Inc.
• Codman Neuro
• Other Key Players

Recent Developments:

January 2022:  Codman Neuro, part of Johnson & Johnson, announced the launch of its new device, the ENVOY Transcarotid Stent System, for the treatment of carotid artery disease and intracranial aneurysms.

October 2021:  Medtronic announced the launch of its Pipeline Flex Embolization Device with Shield Technology, designed to prevent brain aneurysm rupture while preserving blood flow to vital areas of the brain.

July 2021: Cerenovus, a subsidiary of Johnson & Johnson, announced the launch of its new device, the EMBOTRAP III Revascularization Device, for the treatment of ischemic stroke.

Report Scope: